Business Wire

25,000 Health Facilities Across India Are Transforming Public Health Systems to Address Growing Critical Climate Issues

7.4.2023 12:00:00 EEST | Business Wire | Press release

Share

In 2021, WHO identified climate change as the biggest global health threat of the 21st century. While half of the world’s population continue to lack access to essential health services, according to a 2019 Health care climate footprint report, if the healthcare sector were a country, it would be the fifth largest greenhouse gas emitter on the planet.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230407005011/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Aerial view of Khudei Khunou Health facility in North East India (Photo: Business Wire)

In a significant step towards transforming the public health infrastructure for improved sustainability, SELCO Foundation and IKEA Foundation, in partnership with India’s Ministry of Health and Family Welfare (MOHFW) and various State Health Missions, have launched a groundbreaking initiative ‘Energy for Health’. The program recognises climate adaptation and mitigation at the center to all efforts to upgrade the public health facilities across the world.

Speaking about the significance of this program globally, Dr. Maria Neira, Assistant Director-General a.i., Division of Healthier Populations, and Director, Department of Environment, Climate Change and Health, at the World Health Organization said, “Reliable electricity in health-care facilities is essential to save lives and to provide quality health care. And yet, one billion people around the world are still served by health-care facilities without reliable electricity or with no electricity access at all. Decentralized renewable energies represent a key opportunity to accelerate electrification of health-care facilities, including in remote areas. I congratulate the Government of India and our partners from Selco Foundation and Ikea Foundation for this critical program, which will have a transformative impact on strengthening the health system”.

The first-of-a-kind initiative will bring solar energy solutions with efficient medical and electrical equipment to 25,000 healthcare facilities in 12 states by 2026. Across the 12 states under this program, there is a diversity in terms of topography, socio-economic vulnerabilities, disease burden and climate. This diversity across selected geographies will contribute to this programme serving as a showcase globally- innovating on approaches, models and processes relevant for similar contexts in other parts of the world.

Reflecting on India’s leadership in the effort, Dr. Harish Hande, CEO of SELCO Foundation said, “Affordable and equitable access to healthcare is a function of two aspects- one, resources required to deliver health care, and two, cost of accessing health care. Through this program, SELCO Foundation and IKEA Foundation, along with India’s Ministry of Health and Family Welfare (MOHFW) and various State Health Missions, will showcase at scale how sustainable energy can be used to make health services affordable at the doorstep of the poor.”

‘Energy for Health’ initiative brings with it positive impacts across the spectrum of stakeholders- for last mile communities in their access to timely healthcare; for health facility staff in ensuring a conducive work environment to provide quality services; for health sector in reducing energy and equipment-related costs as well as avoiding wastage of vaccines and other critical resources; reinforcing climate resilience building and carbon mitigation efforts while ensuring positive health outcomes for all citizens.

Mr. Per Heggenes, CEO of IKEA Foundation said, “‘At the IKEA Foundation, we strongly believe caring for the health of people and our planet must go hand-in-hand. This initiative will improve healthcare outcomes and reduce emissions, by providing reliable and renewable energy to thousands of clinics. Our hope is that the success of this programme can serve as a model for building effective and efficient health systems globally.’

Supported by IKEA Foundation, through this initiative, SELCO Foundation along with Government of India will create systems and processes that demonstrate ownership, management, and regular maintenance of the energy systems and appliances. Together, through the 25,000 public health facilities, technical knowledge and capacity, as well as guidelines and policies that enable health staff at different levels to plan for public health infrastructure in a sustainable manner will be improved. The program will also improve the local technical network for solar energy, which could potentially also have indirect impacts on local economies and boost adoption of solar energy across other sectors as well.

The initiative aims to reach over 170 million people across the 12 states and improve working conditions for over 160,000 front line health staff at these health facilities. Across the 25,000 public health facilities, this will add ~100MW of solar energy capacity in the country, and mitigate over 3 million tonnes of CO2e emissions over a 20 year period. These will directly contribute to India’s Net Zero targets, while also creating a paradigm shift on how health targets can be achieved for resource constrained communities across the world in an efficient manner.

About the partners:

SELCO Foundation:
Established in 2010, SELCO Foundation’s mission is to develop holistic solutions that use sustainable energy as a catalyst to address poverty alleviation alongside ensuring environmental sustainability. SELCO's interventions lead to the sustainable delivery of essential services such as healthcare, and enable improvements in livelihoods productivity and till date more than 7 million people have been impacted. The foundation does this by also developing enabling conditions, i.e the ecosystem for sustainable energy solutions to be locally developed, adopted, scaled and institutionalized through stakeholders including government agencies, financiers, local NGOs and enterprises.

For more information, visit www.selco foundation.org, and follow them on Twitter (@SELCOFoundation) and LinkedIn.

IKEA Foundation:
The IKEA Foundation is a strategic philanthropy that focuses its grant making efforts on tackling the two biggest threats to children’s futures: poverty and climate change. It currently grants more than €200 million per year to help improve family incomes and quality of life while protecting the planet from climate change. Since 2009, the IKEA Foundation has granted more than €1.5 billion to create a better future for children and their families.

In 2021 the Board of the IKEA Foundation decided to make an additional €1 billion available over the next five years to accelerate the reduction of Greenhouse Gas emissions.

Learn more at: www.ikeafoundation.org or by following them on LinkedIn or Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lotika Mehta
lotika.mehta@ikeafoundation.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye